| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | |
|---|---|---|---|---|---|---|
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | ||||||
160,917 | 89,641 | 86,974 | 69,208 | 60,954 | 65,470 | |
Marketable securities | ||||||
387,618 | 263,432 | 294,472 | 341,725 | 375,641 | 224,938 | |
Prepaid expenses and other current assets | ||||||
7,669 | 4,364 | 4,037 | 3,664 | 5,519 | 2,768 | |
Total current assets | ||||||
556,204 | 357,437 | 385,483 | 414,597 | 442,114 | 293,176 | |
Property and equipment, net | ||||||
32,670 | 33,852 | 33,861 | 32,014 | 21,733 | 10,937 | |
Operating lease right-of-use assets | ||||||
28,179 | 28,476 | 28,765 | 29,058 | 30,665 | - | |
Restricted cash | ||||||
1,472 | 1,472 | 1,472 | 1,472 | 1,472 | 1,472 | |
Other assets | ||||||
403 | 676 | 149 | 110 | 60 | 2,774 | |
Total Assets | ||||||
618,928 | 421,913 | 449,730 | 477,251 | 496,044 | 308,359 | |
Liabilities and stockholders’ equity | ||||||
Current liabilities: | ||||||
Accounts payable | ||||||
4,039 | 278 | 258 | 540 | 1,200 | 126 | |
Accrued clinical supply costs | ||||||
12,315 | 6,706 | 6,412 | 5,981 | 3,723 | 4,463 | |
Accrued liabilities | ||||||
16,709 | 18,256 | 16,546 | 14,577 | 8,000 | 8,439 | |
Deferred revenue, current portion | ||||||
32,089 | 30,165 | 29,527 | 40,871 | 38,526 | 34,905 | |
Deferred rent, current portion | ||||||
- | - | - | - | - | 15 | |
Operating lease liabilities, current portion | ||||||
6,623 | 6,565 | 5,975 | 5,133 | 4,385 | - | |
Total current liabilities | ||||||
71,775 | 61,970 | 58,718 | 67,102 | 55,834 | 47,948 | |
Deferred revenue, long-term portion | ||||||
114,141 | 123,236 | 129,875 | 121,227 | 130,489 | 139,715 | |
Deferred rent, long-term portion | ||||||
- | - | - | - | - | 7,478 | |
Operating lease liabilities, long-term portion | ||||||
40,785 | 41,471 | 42,141 | 42,797 | 43,439 | - | |
Other long-term liabilities | ||||||
493 | 493 | 409 | 409 | 96 | 96 | |
Total liabilities | ||||||
227,194 | 227,170 | 231,143 | 231,535 | 229,858 | 195,237 | |
Convertible preferred stock; $0.0001 par value; zero and 45,849,677 shares authorized as of December 31, 2019 and 2018, respectively; zero and 45,374,836 shares issued and outstanding as of December 31, 2019 and 2018, respectively | ||||||
- | - | - | - | - | 210,520 | |
Stockholders' equity: | ||||||
Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 79,016,469 and 69,052,873 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively | ||||||
8 | 7 | 7 | 7 | 7 | 1 | |
Additional paid-in capital | ||||||
648,783 | 414,414 | 407,647 | 402,823 | 399,066 | 17,078 | |
Accumulated other comprehensive income | ||||||
2,782 | 142 | 226 | 441 | 108 | -42 | |
Accumulated deficit | ||||||
-259,839 | -219,820 | -189,293 | -157,555 | -132,995 | -114,435 | |
Total stockholders' equity | ||||||
391,734 | 194,743 | 218,587 | 245,716 | 266,186 | -97,398 | |
Total liabilities and stockholders’ equity | ||||||
618,928 | 421,913 | 449,730 | 477,251 | 496,044 | 308,359 | |